Declaring Opioid Emergency, Trump Touts FDA Actions, NIH-Industry Partnerships
Proclaiming the opioid epidemic a public health emergency, President points to FDA's prescriber training requirements and withdrawal of Opana ER; Sen. Leahy decries lack of additional funding.
You may also be interested in...
JAMA study finds that removing Rx requirement for naloxone in Ohio resulted in a 2,328% increase in orders of the drug dispensed since 2015. Michael Hufford, CEO of a company working on an OTC switch for a naloxone nasal spray, says the results show urgent need for a low-cost OTC product.
Administration also plans to roll out slate of proposals to decrease drug prices and bring discounts to patients.
With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.